Currently, there are 111.44M common shares owned by the public and among those 107.93M shares have been available to trade.
The company’s stock has a 5-day price change of -6.24% and 4.12% over the past three months. VKTX shares are trading 225.63% year to date (YTD), with the 12-month market performance up to 519.63% higher. It has a 12-month low price of $9.49 and touched a high of $99.41 over the same period. VKTX has an average intraday trading volume of 3.89 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.48%, -6.46%, and -1.16% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Viking Therapeutics Inc (NASDAQ: VKTX) shares accounts for 74.68% of the company’s 111.44M shares outstanding.
It has a market capitalization of $6.75B and a beta (3y monthly) value of 0.93. The earnings-per-share (ttm) stands at -$0.94. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.60% over the week and 7.58% over the month.
Earnings per share for the fiscal year are expected to decrease by -6.58%, and -55.87% over the next financial year. EPS should grow at an annualized rate of 40.00% over the next five years, compared to -18.89% over the past 5-year period.
Looking at the support for the VKTX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on November 04, 2024, with the firm’s price target at $90-$102. JP Morgan coverage for the Viking Therapeutics Inc (VKTX) stock in a research note released on September 11, 2024 offered a Overweight rating with a price target of $80. Morgan Stanley was of a view on June 27, 2024 that the stock is Overweight, while Raymond James gave the stock Strong Buy rating on May 16, 2024, issuing a price target of $115- $116. Oppenheimer on their part issued Outperform rating on March 26, 2024.
